Loading...
Loading...
Bristol-Myers Squibb
BMY and Pfizer Inc.
PFE announced
today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has
approved ELIQUIS® (apixaban) for the prevention of
ischemic stroke and systemic embolism in patients with nonvalvular
atrial fibrillation (NVAF). ELIQUIS is a novel anticoagulant that has
demonstrated risk reductions versus warfarin in three important outcomes
of stroke, major bleeding and all-cause death. ELIQUIS is an oral direct
Factor Xa inhibitor, part of a novel therapeutic class. This is the
third approval for ELIQUIS for the prevention of stroke and systemic
embolism in patients with nonvalvular atrial fibrillation, following
approvals in the European Union and Canada.
“Today's approval of ELIQUIS is
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in